Free Trial

Biomerica (BMRA) Competitors

$0.37
+0.01 (+2.78%)
(As of 07/17/2024 ET)

BMRA vs. AWH, CDIO, MYMD, VRAX, NAVB, SDC, NVST, XRAY, IDXX, and LNTH

Should you be buying Biomerica stock or one of its competitors? The main competitors of Biomerica include Aspira Women's Health (AWH), Cardio Diagnostics (CDIO), MyMD Pharmaceuticals (MYMD), Virax Biolabs Group (VRAX), Navidea Biopharmaceuticals (NAVB), SmileDirectClub (SDC), Envista (NVST), DENTSPLY SIRONA (XRAY), IDEXX Laboratories (IDXX), and Lantheus (LNTH). These companies are all part of the "medical" sector.

Biomerica vs.

Aspira Women's Health (NASDAQ:AWH) and Biomerica (NASDAQ:BMRA) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, community ranking, dividends, risk, media sentiment, institutional ownership, earnings, profitability and analyst recommendations.

12.2% of Aspira Women's Health shares are held by institutional investors. Comparatively, 22.3% of Biomerica shares are held by institutional investors. 4.3% of Aspira Women's Health shares are held by company insiders. Comparatively, 13.5% of Biomerica shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Aspira Women's Health has a beta of 1.54, meaning that its stock price is 54% more volatile than the S&P 500. Comparatively, Biomerica has a beta of -1.08, meaning that its stock price is 208% less volatile than the S&P 500.

Biomerica received 124 more outperform votes than Aspira Women's Health when rated by MarketBeat users. Likewise, 67.82% of users gave Biomerica an outperform vote while only 24.07% of users gave Aspira Women's Health an outperform vote.

CompanyUnderperformOutperform
Aspira Women's HealthOutperform Votes
13
24.07%
Underperform Votes
41
75.93%
BiomericaOutperform Votes
137
67.82%
Underperform Votes
65
32.18%

Biomerica has lower revenue, but higher earnings than Aspira Women's Health. Biomerica is trading at a lower price-to-earnings ratio than Aspira Women's Health, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aspira Women's Health$9.15M1.89-$16.69M-$1.45-0.96
Biomerica$5.34M1.16-$7.14M-$0.37-1.00

Aspira Women's Health presently has a consensus target price of $4.45, suggesting a potential upside of 220.14%. Given Biomerica's higher probable upside, equities analysts plainly believe Aspira Women's Health is more favorable than Biomerica.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aspira Women's Health
0 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.50
Biomerica
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A

Biomerica has a net margin of -117.46% compared to Biomerica's net margin of -163.95%. Biomerica's return on equity of 0.00% beat Aspira Women's Health's return on equity.

Company Net Margins Return on Equity Return on Assets
Aspira Women's Health-163.95% N/A -197.81%
Biomerica -117.46%-64.00%-50.95%

In the previous week, Aspira Women's Health and Aspira Women's Health both had 2 articles in the media. Aspira Women's Health's average media sentiment score of 1.58 beat Biomerica's score of 0.91 indicating that Biomerica is being referred to more favorably in the news media.

Company Overall Sentiment
Aspira Women's Health Positive
Biomerica Very Positive

Summary

Biomerica beats Aspira Women's Health on 9 of the 16 factors compared between the two stocks.

Get Biomerica News Delivered to You Automatically

Sign up to receive the latest news and ratings for BMRA and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BMRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BMRA vs. The Competition

MetricBiomericaDiagnostic substances IndustryMedical SectorNASDAQ Exchange
Market Cap$6.21M$2.90B$5.28B$8.51B
Dividend YieldN/A0.72%2.75%4.02%
P/E Ratio-1.00167.18131.2117.16
Price / Sales1.1651.052,284.44105.02
Price / CashN/A17.9335.1933.66
Price / Book0.533.924.974.55
Net Income-$7.14M$30.88M$110.37M$216.21M
7 Day Performance-11.39%9.33%5.43%5.84%
1 Month Performance-37.39%0.46%8.15%7.18%
1 Year Performance-74.52%-25.22%6.43%3.54%

Biomerica Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AWH
Aspira Women's Health
2.1913 of 5 stars
2.19 / 5 stars
$1.62
+0.6%
$4.45
+174.7%
-53.0%$20.04M$9.15M-1.1264Short Interest ↑
Gap Down
CDIO
Cardio Diagnostics
2.2137 of 5 stars
2.21 / 5 stars
$0.51
-7.3%
$2.00
+295.3%
-51.6%$12.43M$20,000.000.001Positive News
Gap Up
MYMD
MyMD Pharmaceuticals
0 of 5 stars
0.00 / 5 stars
$1.81
+0.6%
N/A-92.1%$4.29MN/A0.006Positive News
VRAX
Virax Biolabs Group
0 of 5 stars
0.00 / 5 stars
$1.13
flat
N/A-67.9%$1.76M$10,000.000.0011Positive News
NAVB
Navidea Biopharmaceuticals
0 of 5 stars
0.00 / 5 stars
$0.00
flat
N/A-99.1%$100,000.00$70,000.00-0.0211
SDC
SmileDirectClub
0 of 5 stars
0.00 / 5 stars
N/AN/AN/A$30.20M$414.88M-0.122,700Gap Down
High Trading Volume
NVST
Envista
4.1387 of 5 stars
4.14 / 5 stars
$15.94
-0.6%
$22.85
+43.4%
-51.9%$2.76B$2.57B-22.1412,800Analyst Forecast
News Coverage
XRAY
DENTSPLY SIRONA
4.7876 of 5 stars
4.79 / 5 stars
$25.56
+0.1%
$34.33
+34.3%
-34.5%$5.30B$3.97B-58.0915,000Gap Up
IDXX
IDEXX Laboratories
4.1648 of 5 stars
4.16 / 5 stars
$482.70
-2.0%
$586.63
+21.5%
-7.0%$40.69B$3.66B46.7311,000Positive News
LNTH
Lantheus
3.9295 of 5 stars
3.93 / 5 stars
$123.19
-0.2%
$113.86
-7.6%
+37.4%$8.55B$1.30B18.81700Analyst Revision

Related Companies and Tools

This page (NASDAQ:BMRA) was last updated on 7/17/2024 by MarketBeat.com Staff

From Our Partners